Company Profile
Compass Therapeutics Stock Price, News & Analysis
- Ticker:
- CMPX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.99 USD (+5.29%)
Close
Last updated: August 6, 2026
375M USD
Market cap
Why the stock is moving
Following the latest company update, “Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update”, CMPX closed up 5.29% at $1.99 on Aug 6, 2026. The move occurred in the trading session associated with this earnings update.
Company overview
Antibody-Based Oncology
Compass Therapeutics develops antibody therapies at the intersection of angiogenesis, tumor immunity and immune suppression. Its portfolio includes bispecific antibodies and immune activators intended to disrupt tumor blood supply while restoring antitumor immune activity.
Tovecimig
Tovecimig is a DLL4 and VEGF-A bispecific antibody being developed with paclitaxel for second-line biliary tract cancer. The Phase 2/3 program showed statistically significant progression-free-survival improvement and signals of an overall-survival benefit, supporting a planned BLA.
CTX-8371
CTX-8371 is a PD-1 and PD-L1 bispecific antibody in Phase 1 development for patients whose tumors progressed after checkpoint inhibitors. Early responses in triple-negative breast cancer, non-small cell lung cancer and Hodgkin lymphoma prompted expansion cohorts in those indications.
CTX-10726 and CTX-471
CTX-10726 combines PD-1 blockade with VEGF-A inhibition and has entered Phase 1 testing in the post-checkpoint setting. CTX-471 is an immune-activating antibody planned for Phase 2 evaluation in tumors expressing NCAM, or CD56.
Future catalysts
Tovecimig meeting with the FDA followed by a planned BLA submission later in 2026.
CTX-8371 dose-escalation and early expansion-cohort data at ASCO 2026, with additional expansion data expected in the fourth quarter of 2026.
Initial Phase 1 data for CTX-10726 expected in the fourth quarter of 2026.
Initiation of a Phase 2 trial of CTX-471 expected in the second half of 2026.
Recent news
- 01
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update
Source: Compass Therapeutics
- 02
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
Source: Compass Therapeutics
- 03
Compass Therapeutics to Participate in Upcoming June Investor Events
Source: Compass Therapeutics
- 04
- 05
Compass Therapeutics to Participate in Upcoming May Investor Events
Source: Compass Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Compass Therapeutics (CMPX)?
Compass Therapeutics (CMPX) most recently closed at 1.99 USD, a +5.29% move versus the previous session.
What is the market cap of Compass Therapeutics (CMPX)?
Compass Therapeutics currently has a market capitalization of 375M USD on BioPharmSignal.
What does Compass Therapeutics do?
Antibody-Based Oncology Compass Therapeutics develops antibody therapies at the intersection of angiogenesis, tumor immunity and immune suppression. Its portfolio includes bispecific antibodies and immune activators intended to disrupt tumor blood supply while restoring antitumor immune activity. Tovecimig Tovecimig is a DLL4 and VEGF-A bispecific antibody...
On which exchange is CMPX stock listed?
Compass Therapeutics (CMPX) is associated with NASDAQ, United States, Biopharma.
What is VEGF-A?
Tovecimig Tovecimig is a DLL4 and VEGF-A bispecific antibody being developed with paclitaxel for second-line biliary tract cancer.
Which conditions is Compass Therapeutics targeting with VEGF-A?
Compass Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Compass Therapeutics describe recent progress with VEGF-A?
Tovecimig meeting with the FDA followed by a planned BLA submission later in 2026. CTX-8371 dose-escalation and early expansion-cohort data at ASCO 2026, with additional expansion data expected in the fourth quarter of 2026. Initial Phase 1 data for CTX-10726 expected in the fourth quarter of 2026. Initiation of a Phase 2 trial of CTX-471 expected in the...
What is CTX-8371?
CTX-8371 CTX-8371 is a PD-1 and PD-L1 bispecific antibody in Phase 1 development for patients whose tumors progressed after checkpoint inhibitors.